选择性孕酮受体调节剂vilaprisan  

A selective progesterone receptor modulator: vilaprisan

作　　者：元凤霞 崔艳丽[2] 肖桂芝[2] 田红[2] YUAN Feng-xia;CUI Yan-li;XIAO Gui-zhi;TIAN Hong(Department of Gynaecology,Tianjin Jinghai District Hospital,Tianjin 301600,China;Tianjin Institute of Pharmaceutical Research,Tianjin 300193,China)

机构地区：[1]天津市静海区医院,天津300160 [2]天津药物研究院,天津300193

出　　处：《现代药物与临床》2018年第11期3074-3078,共5页Drugs & Clinic

摘　　要：子宫肌瘤是子宫内的非癌激素反应性肌肉组织肿瘤,也是最常见的女性生殖系统良性肿瘤,发病机制至今尚不明确。vilaprisan是由拜耳研发的一种新型口服选择性孕酮受体调节剂(SPRM),目前正在患有子宫肌瘤的女性中开展III期临床研究,其有效性和安全性已经得到验证。vilaprisan可能会用于子宫肌瘤有效的长期治疗。主要从vilaprisan的药物概况、相关背景、合成路线、药理作用、临床研究、安全性等方面进行介绍。Uterine fibroids are non-cancerous hormone responsive muscle tumors in the uterus, and also the most common female reproductive system benign tumor. But the pathogenesis is still unclear. Vilaprisan is a noval oral, highly potent, and selective progesterone receptor modulator. At present, the phase III clinical trials of vilaprisan in female with uterine fibroid are in progress and its effectiveness and safety have been confirmed. The drug situation, background, route of synthesis, pharmacological action, clinical research, and safety of vilaprisan are reviewed in this paper.

关 键 词：vilaprisan 选择性孕酮受体调节剂 子宫肌瘤 

分 类 号：R984[医药卫生—药品]